Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Company Abbott Picks Singapore for Trial of New Cancer Drug (Singapore)

This article was originally published in PharmAsia News

Executive Summary

Abbott has recently completed successful Phase I trials of a new cancer drug in Singapore. The company has also announced the selection of Singapore as home to the drug's Phase II trials. Abbott Regional Director Cihangir Kosu says the company chose Singapore because of its "solid infrastructure, high quality of healthcare services, and the existence of outstanding clinical research." The Phase II trials of the drug will occur over a period of six to 18 months. The drug's effectiveness will be tested on between 40 and 60 end-stage cancer patients, as opposed to the 21 tested in the Phase I trials. The new drug works by blocking blood-flow to cancer tumors. Subjects in the Phase I trials saw reductions in tumor size, while avoiding many of the serious side effects associated with most chemotherapy treatments. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066449

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel